IL6 and rheumatoid arthritis: In particular, adalimumab combats the destruction process of the joints observed in RA by reducing the effect of overproduced TNF [33], while tocilizumab competitively inhibits the binding of IL-6 to its receptor, inhibiting the cascades involving the Janus kinase-signal transducer, modulating joint inflammation [34] It has been reported that interleukin 6 is overexpressed in the rheumatoid synovium and in the giant multinucleated cells of the MRH inflammatory infiltrate.